Bioburden Detection: The Hidden Bottleneck in Drug Manufacturing
Bioburden detection is one of the quality control measures required to ensure drug safety –…
Bioburden detection is one of the quality control measures required to ensure drug safety –…
By 2027, the global gene therapy market is estimated to reach a staggering value of…
By 2021, the global biologics market is expected to reach a value of $319B. But…
By 2024, the gene therapy market is expected to reach an estimated worth of $13B…
iOnctura, a spinout from Merck KGaA, has raised €15M to take its cancer and fibrosis…
An international collaboration called BioRescue has taken a step forward in bringing back the Northern…
Update (20/12/2019): After getting conditional approval in Europe in November, Merck has received FDA approval…
Merck will pay the microbiome company 4D Pharma up to €316.5M to develop vaccines based…
Throughout drug discovery and development, emerging biotech companies often find themselves in the predicament of…
The DNA damage repair drug olaparib (Lynparza), developed by AstraZeneca and Merck, has been approved…
The prime goal of an early-stage biotech company after securing funding and implementing the first…
For a small biotech company, funding is a major stepping stone towards future success. But…